# A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML

> **NCT06563804** · PHASE1,PHASE2 · TERMINATED · sponsor: **Servier Bio-Innovation LLC** · enrollment: 13 (actual)

## Conditions studied

- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)/AML
- Chronic Myelomonocytic Leukemia (CMML)

## Interventions

- **DRUG:** S227928
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT06563804
- **Lead sponsor:** Servier Bio-Innovation LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-02-25
- **Primary completion:** 2025-10-09
- **Final completion:** 2025-10-09
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06563804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06563804, "A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06563804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*